Oxidative status and cardiovascular risk in women: Keeping pink at heart

Cristina Vassalle, Antonella Mercuri, Silvia Maffei

INTRODUCTION

It is well known that coronary heart disease (CHD) represents the main cause of mortality and morbidity for men but also for women over age 50 years[1]. However, it has been essentially conceived as a “man’s disease”, and the influence of gender on CHD has been misunderstood and underestimated. Really, mortality due to CHD has not decreased in women as it has in men in the last 20 years, with most women dying suddenly from cardiovascular disease (CVD) without previous symptoms, but with a high prevalence of risk factors for CHD[2].

Generally, the risk for women is misperceived because of the strong conviction that females are “protected” against CVD. This conviction arises from the fact that women are effectively at lower risk of cardiovascular events with respect to men during their first decades of life, being protected by estrogen action in their premenopausal life (Figure 1). However, the onset of menopause marks a crucial point in the woman with important implications also for the cardiovascular system. It is well known that the incidence of CVD is significantly higher in postmenopausal women when compared to those in the same age range who are still fertile[3]. To note, life expectancy for women is greatly increased, and women spend up to one third of their life in their menopause status. Thus, according to the increased possibility of experiencing cardiovascular events, which rapidly rises after the menopause, the advantage gap for
women becomes progressively smaller until it is overcome by that of men in advanced age (Figure 2)\(^8\).

Aspects related to pathogenesis, clinical presentation and outcome of the CHD have not been as extensively studied in women as in men. For a long time, the percentage of women included in CVD trials was always too low\(^9\). Consequently, most current indications for the prevention, diagnosis and therapy are deduced from cohort trials essentially conducted in men, and often result in inappropriate treatment.

However, the deepening of these issues is of particular interest because much evidence indicated that elderly women have even higher mortality and morbidity than men after cardiovascular events. Interestingly, some recent trials on the prevalence of normal or nonobstructive coronary arteries by gender assessed by early angiography after an acute coronary event showed a 20% or greater excess of normal or nonobstructive arteries in women vs men\(^9\). The women with nonobstructive coronary artery disease appeared to have an even higher rate of subsequent adverse events, as indicated by the Women's Ischemia Syndrome Evaluation study\(^10\).

Obviously, if many aspects of CVD are similar in both men and women, some differences concerning physiopathology, risk profile, symptoms, age of onset and response to medical treatments are emerging\(^10\). These differences demonstrate the need of more attention by physicians to address gender disparities\(^10\). Thus, new insights into women's cardiovascular physiopathology are essential in order to assess more accurately and target more specific prevention strategies to reduce CHD risk in female subjects, as well as in men.

**GENDER DIFFERENCES AND CARDIOVASCULAR RISK FACTORS**

The studies focused on the possible gender-related role of different cardiovascular (CV) risk factors, have shown important differences (Table 1)\(^10\). Naturally, hormonal status represents a specific and unique risk factor for women. Moreover, in addition to traditional risk factors, cardio-metabolic risk is an important determinant in women\(^10\).

It is known from examining the lipid profile that total cholesterol, triglycerides, low-density lipoprotein (LDL) and lipoprotein [Lp(a)] increase sharply within 6 mo of menopause onset, while high-density lipoprotein (HDL) gradually declines\(^10\). However, HDL-C is always significantly higher in women than in men; this may be considered a gender-specific protective factor\(^10\). Nonetheless, it has been determined that low HDL-C, rather than high total and LDL-C, represented a more important predictor of CHD in women\(^10\).

Other gender-related differences emerged in a meta-analysis of 17 studies (including 46000 men and 11000 women), which indicated elevated triglycerides as a greater predictor of CV events for women than for men, even after adjustment for HDL-C and other risk factors\(^11\).

Moreover, high levels of Lp(a) were associated with increased CV risk, particularly in women with high levels of LDL-C\(^12\).

Among the inflammatory biomarkers, the addition of C-reactive protein to the Framingham risk score improved the global CV risk prediction in women, especially in those at low-to-intermediate risk\(^13\).

**THE ROLE OF OXIDATIVE STRESS FOR CV RISK IN WOMEN**

Many risk factors that promote CVD have been identified, including hypertension, hypercholesterolemia, diabetes, decreased estrogen in post-menopausal women, increased homocysteine, and cigarette smoking\(^14\). A mechanism common to all these risk factors is the elevation of the oxidative stress status\(^15\). In particular, oxidative stress phenomena occur during the progressive step that characterizes an atherosclerotic lesion from the onset, during its development until the events that induce clinical manifestation of the CVD\(^15\). Consequently, oxidative stress biomarkers have been found by us and others to be associated with the presence and severity of the CVD, and to
the presence and number of risk factors\textsuperscript{16,17}. However, few studies evaluating the risk of CVD in women also included markers of oxidative stress\textsuperscript{18}.

It is known that young women during their fertile life are at lower risk of cardiovascular events compared with men, being protected by estrogen action and that oxidative stress is generally higher in men than in premenopausal women\textsuperscript{19-21,22}. However, after menopause the risk of experiencing cardiovascular events rapidly rises in women, in conjunction with a parallel increase in oxidative stress biomarkers\textsuperscript{19-21,22}. Recent data showed higher levels of biomarkers of inflammation and higher oxidative stress levels in elderly women than in elderly men\textsuperscript{21}. Oxidative stress has been found elevated in post-menopausal women when compared to pre-menopausal women, and recent data has shown that oxidative stress plays a major role in different conditions which often accompany menopause, such as hot flashes and osteoporosis\textsuperscript{23-26}.

Moreover, although oxidative stress results are lower in females compared to males during the first decades of life, this difference decreases until the age range which corresponds to the onset of menopause for women, while for elderly people the tendency is even inverted\textsuperscript{27}.

Although many in vitro data showed the antioxidant properties of estradiol, the role of hormone replacement therapy (HRT) on oxidative stress levels remains still to be demonstrated\textsuperscript{28,29}. However, most of the studies suggested possible beneficial effects or lack of adverse consequences of different doses and formulations of estradiol on the oxidative status in postmenopausal women treated with HRT\textsuperscript{30,31}. Nonetheless, future studies are needed in this field to better clarify the role of different HRT regimens and doses on the oxidative stress balance.

Interestingly, data conducted in patients with neurodegenerative disease showed that female patients presented with higher levels of oxidative stress compared to affected males, suggesting a higher susceptibility to oxidative injury in such female subjects\textsuperscript{32,33}. However, there is a dearth of reliable information on oxidative stress in women in the field of CVD\textsuperscript{34}. We have recently evaluated whether gender-related differences in oxidative stress levels in aged patients with coronary artery disease (CAD) exist. Data obtained showed a higher oxidative stress status in elderly women with respect to men, whereas elevated oxidative stress levels represented the only strong independent risk factor for CAD in elderly women (Figure 3\textsuperscript{35}). At the moment, molecular mechanisms for the overwhelming gender disparity concerning oxidative stress in CAD are unknown, but they are probably related to hormonal status and likely associated with the loss of estrogen-dependent antioxidant effects\textsuperscript{34,35}. Nonetheless, the estimation and correction of levels of oxidative stress might represent a crucial issue in elderly female patients.

With regard to antioxidant vitamin supplementation to prevent CVD, actual guidelines did not recommend its use although folic acid supplementation is advised for high-risk women with high levels of homocysteine\textsuperscript{36,37}. Moreover, two recent trials (Norwegian Vitamin and Heart Outcomes Prevention Evaluation 2) have demonstrated the lack of efficacy of combined supplementation of folic acid and vitamins B12 and B6 in preventing CVD\textsuperscript{38,39}. Conversely, data from the Women’s Health Study suggested that vitamin E failed to provide benefits for either major CV events or myocardial infarction except in women > 65 years of age, where it significantly reduced the risk of major CV events\textsuperscript{40}.

**CONCLUSION**

Emerging data have suggested significant gender-based differences in CVD. In particular, menopausal status appears to enhance the development of CVD through several unfavourable changes in metabolism and hemodynamic parameters. Exploration of these aspects of CVD will provide a basis for clinical strategies directed to improve the outcome for women and consequently

*Table 1: Risk factors for cardiovascular disease in men and women*

| Risk factor | Men | Women |
|-------------|-----|-------|
| Total cholesterol | +++ | +++ |
| LDL | ++ | +++ |
| Triglycerides | + | ++ |
| Apo A-1 | +++ | +++ |
| Apo B | ++ | +(+)
| Smoking | ++ | +(+)
| Diabetes | ++ | +++ |
| Body mass index | ++ | ++ |
| WHR | +++ | +++ |
| Hypertension | ++ | ++ |
| Family history | ++ | +(+)
| Hormones | +++ | +++ |
| Homocysteine | + | + |
| Fibrinogen | + | ++ |
| Inflammation (PCR) | + | ++ |
| Psychosocial factors | + | + |

Modified from Ref. 8.

*Figure 3: Levels of an oxidative stress biomarker by coronary artery disease (CAD) and gender. Modified from: Vassalle C, Maffei S, Boni C, Zucchelli GC. Gender-related differences in oxidative stress levels among elderly patients with coronary artery disease. Fertil Steril 2008; 89: 608-613. *P* < 0.05 vs males; *P* < 0.001 vs both control groups (males and females).*
lead to the discovery and adaptation of different approaches to prevention, diagnosis and management of CVD in women when appropriate.

In particular, recent data on the role of oxidative stress suggested that the estimation of oxidative stress, central to cardiovascular physiopathology, could represent a useful biomarker for cardiovascular risk estimation particularly relevant in elderly female subjects.

REFERENCES

1. Straumba-Badiale M, Fox KM, Priori SG, Collis P, Daly C, Graham I, Jonsson B, Schenk-Gustafsson K, Tendera M. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27: 994-1005

2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Fleg J, O’Donnell C, Kittner S, Lloyd-Jones D, Golf DC Jr, Hong Y, Adams R, Frigay G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151

3. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89: 157-161

4. Oparil S. Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Hypertension 1999; 33: 170-176

5. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 2000; 343: 475-480

6. Anderson RD, Pepine CJ. Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 2007; 115: 823-826

7. Bailey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Pepine CJ, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, Lerman A, Quyyumi AA, Sopko G. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006; 47: S21-S29

8. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 53: 538-549

9. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111: 499-510

10. Rosano GM, Maffei S, Andreassi MG, Vitale C, Vassalle C, Gambacciani M, Straumba-Badiale M, Mercuro G. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown) 2009; 10: 85-92

11. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219

12. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006; 296: 1363-1370

13. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006; 145: 21-29

14. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor Rj, Gianiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouros E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Pettiti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinthorh RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115: 1481-501

15. Forseim IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 2009; 47: 372-381

16. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004; 256: 308-315

17. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brümmer J, Gutzki FM, Berger J, Fritlich JC, Böger RH. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-848

18. Quyyumi AA. Women and ischemic heart disease: pathophysiologic implications from the Women’s Ischemia Syndrome Evaluation (WISE) Study and future research steps. J Am Coll Cardiol 2006; 47: 566-571

19. Baker L, Meldrum KK, Wang M, Sankula R, Vanam R, Raiesdana A, Tsai B, Hile K, Brown JW, Meldrum DR. The role of estrogen in cardiovascular disease. J Surg Res 2003; 115: 325-344

20. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002; 53: 550-557

21. Gebara OC, Mittleman MA, Sutherland P, Liptonska I, Matheny T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-1958

22. Gierach GL, Johnson BD, Bairey Merz CN, Kelsey SF, Bittner V, Olson MB, Shaw LJ, Mankad S, Pepine CJ, Reis SE, Rogers WJ, Sharaf BL, Sopko G. Hypertension, menopause, and coronary artery disease risk in the Women’s Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol 2006; 47: 550-558

23. Agrawal A, Loenne RV, Gupta S, La Cava A. Gender-Based Differences in Leptinemia in Healthy Aging, Non-obese Individuals Associate with Increased Marker of Oxidative Stress. Int J Clin Exp Med 2008; 1: 305-309

24. Leal M, Díaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000; 95: 804-809

25. Altindag O, Orel O, Soran N, Celik H, Selek S. Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int 2008; 28: 317-321

26. Grassi F, Tell G, Robbie-Ryan M, Gao Y, Terauchi M, Yang X, Romanellio M, Jones DP, Weitzmann MN, Pacinifi C. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci USA 2007; 104: 15087-15092

27. Miquel J, Ramirez-Boscá A, Soler A, Diez A, Carrión-Gutiérrez MA, Díaz-Alperni J, Quintanilla-Ripoll E, Bernd A, Quintanilla-Almagro E. Increase with age of serum lipid peroxides: implications for the prevention of atherosclerosis. Mech Ageing Dev 1998; 100: 17-24

28. Strehlow K, Rotter S, Wassmann S, Adam O, Grohé C,
Vassalle C et al. Cardiovascular disease in women

Laufs K, Böhm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003; 93: 170-177

Maffei S, Mercuri A, Prontera C, Zucchelli GC, Vassalle C. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy. Climacteric 2006; 9: 452-458

Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T. Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chim Acta 2006; 369: 73-77

Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002; 9: 244-248

Schuessel K, Leutner S, Cairns NJ, Müller WE, Eckert A. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J Neural Transm 2004; 111: 1167-1182

Vassalle C, Maffei S, Boni C, Zucchelli GC. Gender-related differences in oxidative stress levels among elderly patients with coronary artery disease. Fertil Steril 2008; 89: 608-613

Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 1998; 138: 255-262

Huang M, Li J, Teoh H, Man RY. Low concentrations of 17beta-estradiol reduce oxidative modification of low-density lipoproteins in the presence of vitamin C and vitamin E. Free Radic Biol Med 1999; 27: 438-441

Davey Smith G, Ebrahim S. Folate supplementation and cardiovascular disease. Lancet 2005; 366: 1679-1681

Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296: 2720-2726

Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588

Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577

Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 56-65

S- Editor Wang JL  L- Editor O'Neill M  E- Editor Zheng XM